Pathophysiology and current understanding of degenerative disc disease

Table 4 Therapeutic options in degenerative disc disease

Category	Therapy	Main features	Benefits and limitations
Conservative management	Physical therapy. Lifestyle modifications (weight loss, smoking cessation, ergonomics)	Strengthens core and paraspinal muscles. Improves posture and flexibility	Reduces mechanical strain. First-line therapy. Requires adherence
	Lifestyle modifications (weight loss, smoking cessation, ergonomics)	Addresses modifiable risk factors	Slows degeneration. Non-invasive. Patient-dependent
	Pharmacological therapy (NSAIDs, muscle relaxants, analgesics)	NSAIDs ↓ COX activity and prostaglandins. Analgesics reduce pain	Short-term relief; risks include gastrointestinal, renal, cardiovascular side effects
Medical pain management	NSAIDs	Anti-inflammatory via COX inhibition	Short-term relief. Limited disc penetration. Systemic risks
	Opioids	Activate G-protein coupled receptor pathways → inhibit neurotransmission	Effective for severe pain. High risk of addiction and dependence
	Muscle relaxants	Reduce muscle spasm	Symptomatic relief. Sedation risk
	Epidural corticosteroid injections	Reduce inflammation via COX and arachidonic acid inhibition	Temporary relief. Systemic steroid effects. No long-term benefit
Emerging pharmacologic therapies	Pamidronate	Bisphosphonate inhibiting osteoclasts and bone turnover	Potential pain reduction. Investigational
	Abaloparatide	Osteoporosis drug shown to reduce IVD degeneration (animal models)	Experimental. No established human benefit
	Alpha-2-macroglobulin	Protease inhibitor targeting FAC	Under investigation for slowing degeneration
Surgical management	Discectomy and decompression	Removes herniated disc tissue → relieves nerve compression	Effective for stenosis/herniation. Does not halt degeneration
	Spinal fusion	Removes disc → inserts cage + hardware. Eliminates motion	Pain reduction. Decreases mobility. Adjacent segment disease
	Total disc replacement	Replaces disc with motion-preserving prosthesis	Preserves mobility. Modest benefits vs fusion. Long-term data limited
Biological and regenerative therapies	Platelet-rich plasma	Growth factors (PDGF, VEGF, IGF-1, TGF-β) stimulate ECM synthesis	Promising early results. Inconsistent human data. No standardized protocols available
	Stem cell therapies	Implantation of regenerative cells into disc to restore ECM and hydration	Early promise. Challenges: Cell survival; microenvironment; delivery
	Growth factor therapy (TGF-β, BMP-7)	Enhances matrix production	Experimental. Limited human evidence
	Gene therapy	Introduces genes to enhance matrix synthesis or reduce catabolism	Highly experimental. Delivery and safety challenge

NSAID: Nonsteroidal anti-inflammatory drugs; COX: Cyclooxygenase; IVD: Intervertebral disc; FAC: Fibronectin-aggrecan complex; PDGF: Platelet-derived growth factor; VEGF: Vascular endothelial growth factor; IGF-1: Insulin-like growth factor 1; TGF-β: Transforming growth factor-β; ECM: Extracellular matrix; BMP-7: Bone morphogenetic protein 7.